Mainstay Medical International plc

Mainstay Medical secured $108m to support the US launch of its ReActiv8 device for treating back pain, along with continued commercialization of the device in Europe and Australia. The financing, ann

Fountain Healthcare Partners of Ireland has put together its third life sciences fund, raising €125m -exceeding its initial target of €100m - and earmarked most of it for European companies. The new f

Mainstay Medical International PLC believes it has enough data to move forward with a PMA application to US FDA for its ReActiv8 implantable spinal neuromodulator device to treat chronic back pain,

Chronic pain afflicts more than one billion people worldwide and there are over 100 deaths caused by opioid overdose in the US alone, creating the need for safer and more effective pain therapy, accor